Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples

Translational Oncology

Volumn 7, Issue 3, 2014, Pages 363-367

  Zhao, Chao ^a   Li, Xuefei ^a   Li, Jiayu ^b   Zhang, Yishi ^b   Ren, Shengxiang ^b   Chen, Xiaoxia ^b   Zhou, Caicun ^b  

^a TONGJI UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84922769881     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.04.013     Document Type: Article

References (31)

1. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J Clin 61 (2011), 69–90.
2. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004), 2129–2139.
3. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
4. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 (2004), 13306–13311.
5. Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561–566.
6. Koivunen, J.P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A.J., Choi, H.G., Kim, J., Chiang, D., Thomas, R., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14 (2008), 4275–4283.
7. Takeuchi, K., Choi, Y.L., Soda, M., Inamura, K., Togashi, Y., Hatano, S., Enomoto, M., Takada, S., Yamashita, Y., Satoh, Y., et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14 (2008), 6618–6624.
8. Inamura, K., Takeuchi, K., Togashi, Y., Nomura, K., Ninomiya, H., Okui, M., Satoh, Y., Okumura, S., Nakagawa, K., Soda, M., et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3 (2008), 13–17.
9. Choi, Y.L., Takeuchi, K., Soda, M., Inamura, K., Togashi, Y., Hatano, S., Enomoto, M., Hamada, T., Haruta, H., Watanabe, H., et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68 (2008), 4971–4976.
10. Takeuchi, K., Choi, Y.L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15 (2009), 3143–3149.
11. Shaw, A.T., Yeap, B.Y., Mino-Kenudson, M., Digumarthy, S.R., Costa, D.B., Heist, R.S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27 (2009), 4247–4253.
12. Wu, S.G., Kuo, Y.W., Chang, Y.L., Shih, J.Y., Chen, Y.H., Tsai, M.F., Yu, C.J., Yang, C.H., Yang, P.C., EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 7 (2012), 98–104.
13. Kwak, E.L., Bang, Y.J., Camidge, D.R., Shaw, A.T., Solomon, B., Maki, R.G., Ou, S.H., Dezube, B.J., Janne, P.A., Costa, D.B., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363 (2011), 1693–1703.
14. Bergethon, K., Shaw, A.T., Ou, S.H., Katayama, R., Lovly, C.M., McDonald, N.T., Massion, P.P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30 (2012), 863–870.
15. Lovly, C.M., Heuckmann, J.M., de Stanchina, E., Chen, H., Thomas, R.K., Liang, C., Pao, W., Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 71 (2011), 4920–4931.
16. Rimkunas, V.M., Crosby, K.E., Li, D., Hu, Y., Kelly, M.E., Gu, T.L., Mack, J.S., Silver, M.R., Zhou, X., Haack, H., Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 18 (2012), 4449–4457.
17. Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131 (2007), 1190–1203.
18. Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18 (2012), 375–377.
19. Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 18 (2012), 378–381.
20. Suehara, Y., Arcila, M., Wang, L., Hasanovic, A., Ang, D., Ito, T., Kimura, Y., Drilon, A., Guha, U., Rusch, V., et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 18 (2012), 6599–6608.
21. Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J.A., Balasubramanian, S., Bloom, T., Brennan, K.W., et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18 (2012), 382–384.
22. Cavalli, P., Riboli, B., Generali, D., Passalacqua, R., Bosio, G., EGFR genotyping in pleural fluid specimens in NSCLC patients. Lung Cancer 54 (2006), 265–266.
23. Kimura, H., Fujiwara, Y., Sone, T., Kunitoh, H., Tamura, T., Kasahara, K., Nishio, K., EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 95 (2006), 1390–1395.
24. Sanz-Santos, J., Serra, P., Andreo, F., Llatjos, M., Castella, E., Monso, E., Contribution of cell blocks obtained through endobronchial ultrasound-guided transbronchial needle aspiration to the diagnosis of lung cancer. BMC cancer, 12, 2012, 34.
25. Shaw, A.T., Solomon, B., Kenudson, M.M., Crizotinib and testing for ALK. J Natl Compr Canc Netw 9 (2011), 1335–1341.
26. Sasaki, H., Shimizu, S., Tani, Y., Maekawa, M., Okuda, K., Yokota, K., Shitara, M., Hikosaka, Y., Moriyama, S., Yano, M., et al. RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer. Cancer Med 1 (2012), 68–75.
27. Soda, M., Isobe, K., Inoue, A., Maemondo, M., Oizumi, S., Fujita, Y., Gemma, A., Yamashita, Y., Ueno, T., Takeuchi, K., et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res 18 (2012), 5682–5689.
28. Cai, G., Wong, R., Chhieng, D., Levy, G.H., Gettinger, S.N., Herbst, R.S., Puchalski, J.T., Homer, R.J., Hui, P., Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol 121 (2013), 500–507.
29. Cai, W., Su, C., Li, X., Fan, L., Zheng, L., Fei, K., Zhou, C., KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. Cancer 119 (2013), 1486–1494.
30. Rodig, S.J., Mino-Kenudson, M., Dacic, S., Yeap, B.Y., Shaw, A., Barletta, J.A., Stubbs, H., Law, K., Lindeman, N., Mark, E., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15 (2009), 5216–5223.
31. Scagliotti, G., Stahel, R.A., Rosell, R., Thatcher, N., Soria, J.C., ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer 48 (2012), 961–973.